Ion channel diseases of the central nervous system

CNS Drug Reviews

Volumn 7, Issue 2, 2006, Pages 214-240

  Li, Ming ^a   Lester, Henry A ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alzheimer's disease; Ataxia; Epilepsy; Ion channels; Schizophrenia

Indexed keywords

ION CHANNEL;

ALZHEIMER DISEASE; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; EPILEPSY; GENE MUTATION; HUMAN; MIGRAINE; NONHUMAN; REVIEW; SCHIZOPHRENIA;

EID: 0034953943     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00196.x     Document Type: Review

References (179)

1. Synaptic inhibition of the M-current: Slow excitatory post-synaptic potential mechanism in bullfrog sympathetic neurones
2. Episodic ataxia results from voltage-dependent potassium channels with altered functions
3. Rasmussen's encephalitis: An autoimmune disorder?
4. + channel blocker
5. Familial episodic ataxia: Clinical heterogeneity in four families linked to chromosome 19p
6. The influence of Bay K 8644 treatment on (+/-)-epibatidine-induced analgesia
7. Donepezil use in Alzheimer disease
8. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33
9. Members of the RCK potassium channel family are differentially expressed in the rat nervous system
10. Primary and secondary cerebral lesions produced by kainic acid injections in the rat
11. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits
12. A potassium channel mutation in neonatal human epilepsy
13. 3 receptor in CNS disorders
14. 5-HT antagonists attenuate MK801-impaired radial arm maze performance in rats
15. The pharmacology of (-)-nicotine and novel cholinergic channel modulators
16. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test
17. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice
18. 3 antagonist on drug-induced stimulation of dopamine release
19. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
20. Stargazing regulates synaptic targeting of AMPA receptors by two distinct mechanisms
21. 7-nicotinic receptor subunit gene (CHRNA7)
22. Glutamate receptors and the induction of excitotoxic neuronal death
23. On recurrent motor paralysis in migraine, with report of a family in which recurrent hemiplegia accompanied the attacks
24. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy
25. Zacopride: Anxiolytic profile in rodent and primate models of anxiety
26. Actions of buspirone in a putative model of anxiety in the mouse
27. 3 subunit of the type A γ-aminobutyric acid receptor
28. Calcium agonists and antagonists of the dihydropyridine type: Effect on nicotine-induced antinociception and hypomotility
29. 2 subunit is mutant in nocturnal frontal lobe epilepsy
30. Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats
31. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
32. Expression of the alpha 4 neuronal nicotinic acetylcholine receptor subunit in the developing mouse hippocampus
33. Excitotoxic injury of the neostriatum: A model for Huntington's disease
34. Mutations in the Cacnlla4 calcium channel gene are associated with seizures, cerebellar degeneration, and ataxia in tottering and leaner mutant mice
35. Adenosine: A potential mediator of seizure arrest and postictal refractoriness
36. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures
37. Cognition enhancement strategies by ion channel modulation of neurotransmission
38. Gene table: Epilepsy (update)
39. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q
40. Mutations of SCNIA, encoding a neuronal sodium channel, in two families with GEFS+2
41. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
42. Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization
43. Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response
44. The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits
45. Absence epilepsy in tottering mutant mice is associated with calcium channel defects
46. Therapeutic potential of NMDA receptor antagonists as neuroprotective agents
47. Biological phenotypes in the genetics of schizophrenia
48. Selection of digital filtering parameters and P50 amplitude
49. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
50. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia
51. A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1
52. Increased expression of the embryonic form of a developmentally regulated mRNA in Alzheimer's disease
53. Excitatory amino acids and Alzheimer's disease
54. Episodic ataxias as channelopathies
55. Nomenclature of mammalian voltage-dependent potassium channel genes
56. 3 receptors and cerebral dopamine function: Implications for the treatment of schizophrenia and psychoactive substance abuse
57. 1A calcium channel subunit linked to familial hemiplegic migraine
58. Mutant mice lacking the gamma isoform of protein kinase C show decreased behavioral actions of ethanol and altered function of gamma-aminobutyrate type A receptors
59. 3H]prazosin binding sites in the rat frontal cortex
60. Autosomal dominant nocturnal frontal lobe epilepsy: Demonstration of focal frontal onset and intrafamilial variation
61. Pharmacotherapy of Alzheimer dementia: Therapy of cognitive symptoms - New results of clinical studies
62. Alzheimer's congress. Further progress on a beta-amyloid vaccine
63. Increased AMPA-sensitive quisqualate receptor binding and reduced NMDA receptor binding in epileptic human hippocampus
64. Mutating a gene for a potassium channel by hybrid dysgenesis: An approach to the cloning of the Shaker locus in Drosophila
65. Pharmacology and clinical efficacy of cholinesterase inhibitors
66. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p
67. A) receptor complex and hepatic encephalopathy. Some recent advances
68. Entorhinal-hippocampal connections: A speculative view of their function
69. A gene for familial hemiplegic migraine maps to chromosome 19
70. Genetic heterogeneity of familial hemiplegic migraine
71. Multiple products of the Drosophila Shaker gene may contribute to potassium channel diversity
72. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist
73. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats
74. Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia
75. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys
76. Effects of the antiparkinsonian drug budipine on central neurotransmitter systems
77. + channel and rescue of weaver granule cells
78. A receptor
79. A locus for the nystagmus-associated form of episodic ataxia maps to an 11-cM region on chromosome 19p
80. 2+ channel kinetics
81. Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons
82. Parental imprinting and Angelman syndrome
83. Serotonin receptors and therapeutics
84. Benign familial neonatal convulsions linked to genetic markers on chromosome 20
85. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease
86. Nicotinic acetylcholine receptors in health and disease
87. Molecular studies of the neuronal nicotinic acetylcholine receptor family
88. A gene for episodic ataxia/myokymia maps to chromosome 12p13
89. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans
90. Voltage-gated potassium channel genes are clustered in paralogous regions of the mouse genome
91. Huntington's disease: Translating a CAG repeat into a pathogenic mechanism
92. Antiepileptic drug mechanisms of action
93. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
94. Confirmation of linkage of benign familial neonatal convulsions to D20S19 and D20S20
95. Nicotinic autoreceptors mediating enhancement of acetylcholine release become operative in conditions of "impaired" cholinergic presynaptic function
96. Effect of riluzole on quinolinate-induced neuronal damage in rats: Comparison with blockers of glutamatergic neurotransmission
97. Molecular features of the CAG repeats of spinocerebellar ataxia 6 (SCA6)
98. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
99. Toward an understanding of the dihydropyridine-sensitive calcium channel
100. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
101. Cellular and molecular basis of epilepsy
102. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy
103. Excitatory amino acid receptors and disease
104. Differential distribution of closely related potassium channels in rat Schwann cells
105. 2+ release
106. Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFS+) on chromosome 2q24-q33
107. Acetylcholine, aging, and Alzheimer's disease
108. Effects of the conventional anticonvulsants, phenytoin, carbamazepine, and valproic acid, on sodium-potassium-adenosine triphosphatase in acute ischemic brain
109. A receptor subunit genes is deleted in a neurological mutant of the mouse p locus
110. + channels
111. Biological markers and the cholinergic hypothesis in Alzheimer's disease
112. Neuroreceptor changes in Alzheimer disease
113. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment
114. A case with nocturnal paroxysmal unilateral dystonia and interictal right frontal epileptic EEG focus: A lateralized variant of nocturnal paroxysmal dystonia?
115. 2+ channel gene CACNL1A4
116. Genetic heterogeneity of familial hemiplegic migraine
117. Cloning and mapping of the mouse alpha 7-neuronal nicotinic acetylcholine receptor
118. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila
119. Cognitive enhancement therapy for Alzheimer's disease. The way forward
120. Anticonvulsant activity of the NMDA antagonists, D(-)4-(3-phosphonopropyl)piperazine-2-carboxylic acid (D-CPP) and D(-)(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (D-CPPene) in a rodent and a primate model of reflex epilepsy
121. Stereotactic location and excision of seizure focus with xenon-enhanced CT
122. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation
123. Electron microscopic localization of Alzheimer neurofibrillary tangle components recognized by an antiserum to paired helical filaments
124. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2
125. Autosomal dominant nocturnal frontal-lobe epilepsy: Genetic heterogeneity and evidence for a second locus at 15q24
126. Serotonin: Neurotransmitter "a la mode." Report on the Third International I.T.E.M.-LABO symposium on strategies in psychopharmacology. Serotonin: Animal models and clinical targets
127. Focal seizures due to chronic localized encephalitis
128. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents
129. Transient increase of NMDA-binding sites in human hippocampus during development
130. Neugeborenen krämpfe im rahmen einer epileptisch belasten familie
131. A receptors by barbiturates in cultured rat hippocampal neurons
132. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis
133. Seizure characteristics in chromosome 20 benign familial neonatal convulsions
134. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity
135. Facilitation of memory by post-trial administration of nicotine: Evidence for an attentional explanation
136. Anatomical, physiological, and theoretical basis for the antiepileptic effect of vagus nerve stimulation
137. Tetrahydroaminoacridine (THA) in Alzheimer's disease: An assessment of attentional and mnemonic function using CANTAB
138. Genetic modification of potassium channels in Drosophila Shaker mutants
139. Seizure associated with ondansetron
140. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes
141. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder
142. Locus for febrile seizures
143. 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia
144. A regenerative link in the ionic fluxes through the weaver potassium channel underlies the pathophysiology of the mutation
145. Generalized epilepsy with febrile seizures plus: A common childhood-onset genetic epilepsy syndrome
146. Deletion of the K(V)1.1 potassium channel causes epilepsy in mice
147. 4 with common idiopathic generalized epilepsies
148. Benign familial neonatal convulsions: Confirmation of genetic heterogeneity and further evidence for a second locus on chromosome 8q
149. An insertion mutation of the CHRNA4 gene in a family with autosomal dominant nocturnal frontal lobe epilepsy
150. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy
151. Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins
152. Amplification of EPSPs by axosomatic sodium channels in neocortical pyramidal neurons
153. Cholinergic channel activators: Novel opportunities for the treatment of CNS disorders
154. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy
155. Action potentials in normal and Shaker mutant Drosophila
156. + channels as targets for neuroprotective drugs
157. Expression of a serotonin-gated ion channel in embryonic neural and nonneural tissues
158. Cloning of a probable potassium channel gene from mouse brain
159. The weaver mutation changes the ion selectivity of the affected inwardly rectifying potassium channel GIRK2
160. Basis of the antiseizure action of phenytoin
161. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site
162. + channels: A rational and effective strategy against ischemic brain damage
163. A gene for hereditary paroxysmal cerebellar ataxia maps to chromosome 19p
164. Cognition-enhancing drugs in dementia: A guide to the near future
165. Immunohistochemical localization of five members of the Kv1 channel subunits: Contrasting subcellular locations and neuron-specific co-localizations in rat brain
166. Mapping the gene for acetazolamide responsive hereditary paryoxysmal cerebellar ataxia to chromosome 19p
167. 1 subunit gene SCNI B
168. + channels in terminal and juxtaparanodal regions of neurons
169. Localization of Kv1.1 and Kv1.2, two K channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain
170. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
171. Affinity labelling of neuronal acetylcholine receptors localizes acetylcholine-binding sites to their beta subunits
172. Expression of nicotinic acetylcholine receptor subtypes in brain and retina
173. Immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis
174. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
175. Current approaches to the treatment of Alzheimer's disease
176. Cytogenetic and clinical studies in five cases of inv dup(15)
177. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice
178. 1A-voltage-dependent calcium channel
179. Lamotrigine - Antiparkinsonian activity by blockade of glutamate release?